Jenburkt Pharmaceuticals Ltd (JENBURPH) — shareholding pattern, promoter holding, financials and share price
About Jenburkt Pharmaceuticals Ltd (JENBURPH)
Jenburkt Pharmaceuticals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as JENBURPH and on the BSE under scrip code 524731. Its ISIN is INE354A01013.
Incorporated in 1985, Jenburkt Pharmaceuticals Ltd manufactures and markets branded Pharmaceuticals and health care products [1]
Jenburkt Pharmaceuticals Ltd is a company engaged in the manufacturing and marketing of pharmaceutical formulations and healthcare products both in India and internationally.
The company operates a manufacturing plant in Gujarat that complies with WHO guidelines, demonstrating its commitment to quality and global standards.
Listed peers in Pharmaceuticals: Zim Laboratories Ltd, Haleos Labs Limited, Bafna Pharmaceuticals Ltd, Transchem Ltd, Albert David Ltd, Aptus Pharma Ltd.
Valuation & Returns
10 Jul 2026At ₹1,114.79 a share on 10 Jul 2026, Jenburkt Pharmaceuticals Ltd (JENBURPH) was valued at a price-to-earnings ratio of 14.17x against an industry P/E of 36.41x and a price-to-book of 2.86x on a book value of ₹389.23 per share as of Mar 2025. Solomo computes return on equity of 20.22% and return on capital employed of 26.75% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 14.17x
- Industry P/E
- 36.41x
- P/B
- 2.86x
- EPS (TTM)
- ₹78.69
- Book value / share
- ₹389.23
- ROE
- 20.22%
- ROCE
- 26.75%
- ROA
- 17.7%
- Debt / equity
- 0.02x
- Dividend yield
- 1.61%
- EBITDA margin
- 29.68%
- 52-week range
- ₹944 – ₹1,384
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Jenburkt Pharmaceuticals Ltd (JENBURPH) reported revenue of ₹169 crore, net profit of ₹35 crore and earnings per share of ₹78.72. That compares with revenue of ₹152 crore and net profit of ₹32 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹45 crore and net profit ₹11 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 124 | 137 | 142 | 152 | 169 |
| Net profit (₹ cr) | 22 | 25 | 26 | 32 | 35 |
| EPS (₹) | 48.59 | 55.76 | 58.87 | 72.64 | 78.72 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 5.34% | 4.99% | 6.96% | 6.85% |
| Profit growth | 12.88% | 16.61% | 12.87% | 23.40% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 46.62% of Jenburkt Pharmaceuticals Ltd (JENBURPH) (down 0.02 pp QoQ) and domestic institutional investors (DII) hold 0.12%. Market capitalisation was ₹492 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: NIRMALA VINODKUMAR DAGA 3.3%, INVESTOR EDUCATION AND PROTECTION FUND AUTHORITY 2.32%, RANJEET SINGH SIBIA 1.5%, HUF 1.23%, OPTIRATIONAL VENTURES LLP 1.2%, RAJIV GARG 1.07%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 46.62% | - | - | 0.12% | 53.38% |
| Mar 2026 | 46.64% | - | - | 0.12% | 53.36% |
| Dec 2025 | 46.65% | - | - | 0.12% | 53.35% |
| Sep 2025 | 46.66% | - | - | 0.12% | 53.34% |
| Jun 2025 | 46.67% | - | - | 0.12% | 53.33% |
| Mar 2025 | 46.68% | - | - | 0.12% | 53.32% |
| Dec 2024 | 46.69% | - | - | 0.12% | 53.31% |
| Sep 2024 | 46.71% | - | - | - | 53.29% |